Nature Communications (Dec 2022)
Targeting cardiomyocyte ADAM10 ectodomain shedding promotes survival early after myocardial infarction
- Erik Klapproth,
- Anke Witt,
- Pauline Klose,
- Johanna Wiedemann,
- Nikitha Vavilthota,
- Stephan R. Künzel,
- Susanne Kämmerer,
- Mario Günscht,
- David Sprott,
- Mathias Lesche,
- Fabian Rost,
- Andreas Dahl,
- Erik Rauch,
- Lars Kattner,
- Silvio Weber,
- Peter Mirtschink,
- Irakli Kopaliani,
- Kaomei Guan,
- Kristina Lorenz,
- Paul Saftig,
- Michael Wagner,
- Ali El-Armouche
Affiliations
- Erik Klapproth
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Anke Witt
- Department of Physiology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Pauline Klose
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Johanna Wiedemann
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Nikitha Vavilthota
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Stephan R. Künzel
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Susanne Kämmerer
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Mario Günscht
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- David Sprott
- Department of Physiology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Mathias Lesche
- DRESDEN-concept Genome Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden
- Fabian Rost
- DRESDEN-concept Genome Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden
- Andreas Dahl
- DRESDEN-concept Genome Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden
- Erik Rauch
- Endotherm GmbH
- Lars Kattner
- Endotherm GmbH
- Silvio Weber
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Peter Mirtschink
- Institute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Irakli Kopaliani
- Department of Physiology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Kaomei Guan
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Kristina Lorenz
- Institute of Pharmacology and Toxicology, Julius-Maximilians-University of Würzburg
- Paul Saftig
- Biochemical Institute, Christian-Albrechts-Universität Kiel
- Michael Wagner
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- Ali El-Armouche
- Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden
- DOI
- https://doi.org/10.1038/s41467-022-35331-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Therapeutic interference with the immune response after myocardial infarction holds the potential to close a clinically relevant gap. Here, the authors show that inhibition of a cardiomyocyte-specific ADAM10 / CX3CL1 axis improves post infarction survival and cardiac function by attenuating neutrophil-mediated myocardial damage.
